Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects.
about
Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug developmentGender analysis of moxifloxacin clinical trialsPharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensEfficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 studyTelavancin: a new lipoglycopeptide with multiple mechanisms of action.Role of telavancin in treatment of skin and skin structure infectionsTelavancin (vibativ), a new option for the treatment of gram-positive infectionsPopulation pharmacokinetics of telavancin in healthy subjects and patients with infections.Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.Treatment options for multidrug-resistant bacteria.Investigational treatments for postoperative surgical site infections.Telavancin: a novel lipoglycopeptide for serious gram-positive infections.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year periodA review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).Telavancin: a novel lipoglycopeptide antibiotic.Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteersSingle-dose pharmacokinetics and tolerability of telavancin in elderly men and women.Electrocardiographic QTc changes due to moxifloxacin infusion.Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects.Periprosthetic joint infections: clinical and bench research.
P2860
Q24646866-9BDB7462-04EF-4521-A8A7-690828C2A6D1Q28538319-68E2E5EE-A30B-435C-85A8-3A413C1AB90BQ33554391-0C8EDA80-F81E-4AA3-9686-035E0B583FF1Q33788308-A10EECC1-7264-414C-8B02-87D43798978CQ34390763-3039627A-28F7-4A9D-98F7-98D4D1B05504Q34509652-8DD6A504-CF02-41B9-BC83-F2501C11592EQ34572923-3CF9182D-B67C-40BE-A285-36B12D2EEEDFQ34620329-4DEF7B78-EBCA-42F8-9247-5B8818CBC3B5Q34906520-B78094A3-E4FF-47BC-8B44-8E0491BEEF18Q35867522-55C5E3B8-C3EF-402A-AB13-55479D50E56AQ36073405-417F554A-53F2-4F09-8134-45782073AFF0Q36422696-1F0339CB-AC5A-44D5-A52F-D4BED7571D94Q36607401-BDC86E25-57F9-49D9-8512-56AD8FF90C7CQ36715742-641F7194-A01D-4107-96E4-735619D65C36Q36736356-695A9650-CDFF-454B-9038-3D972EB1C86FQ37071199-7C598158-A4C5-44C0-ADDF-FEEA38FD0E84Q37077627-F3C77932-8DBF-4D8C-94BA-85AD74E7ABAEQ37117865-04A94722-8436-46E6-88C9-5D653CB9318AQ37156289-BDC9E2F9-35E0-4725-AAB0-30999AB32DF6Q37252733-56FA9A96-CA4C-436D-B7F8-7121141F3470Q37463589-6EB7053F-5866-44CD-8B50-9BCCA7C8944CQ37955286-E94B6DA1-7A17-4EC4-854E-33B781330BACQ38048845-8457B551-33E7-41F4-9CC0-2CD02D744E59Q38646905-034CD392-103F-4AE2-AA5F-997B18D9972DQ38829519-64F3EC97-E54D-4F6C-85E0-1713B3382E18Q40317287-8B9DDC26-8147-48D1-9690-0CD5E09B7F82Q42576977-55A5EC26-A760-4FF2-A781-F82DD9B7EAB4Q44935039-F3571423-E17B-4D2E-9127-A165C589B055Q46006812-69F15BED-A0DE-41B4-AF31-1EE43E7715AAQ46587405-296A82C7-3C31-432A-84DC-1420710B71FEQ53663173-C13AFCC1-5D3B-4EF6-B42C-EB63EAD509C0
P2860
Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Effects of a new antibacterial ...... duration) in healthy subjects.
@en
Effects of a new antibacterial ...... duration) in healthy subjects.
@nl
type
label
Effects of a new antibacterial ...... duration) in healthy subjects.
@en
Effects of a new antibacterial ...... duration) in healthy subjects.
@nl
prefLabel
Effects of a new antibacterial ...... duration) in healthy subjects.
@en
Effects of a new antibacterial ...... duration) in healthy subjects.
@nl
P2093
P2860
P356
P1476
Effects of a new antibacterial ...... duration) in healthy subjects.
@en
P2093
David Hoelscher
Elizabeth Spencer
Fredric Genter
Joel Morganroth
Michael Kitt
Steven Barriere
P2860
P304
P356
10.1177/0091270004266620
P577
2004-07-01T00:00:00Z